Munich-based patient support software company XO Life, which offers real-time patient insights and feedback across various treatments and indications, has secured €7 million. The fresh funding will allow the startup to expand its ImpactMonitor platform globally.
- Established in 2018 by Johannes Bachhuber and Friderike Bruchmann, XO Life develops the ImpactMonitor platform. The platform collects long-term patient insights through real-world data, facilitating real-time information exchange between patients and the pharmaceutical industry.
- The ImpactMonitor platform enhances understanding and improves patient care, aiming to set the gold standard for digital treatment monitoring and patient feedback in research, development, marketing, and sales, all while upholding the highest standards of data protection and security.
"With ImpactMonitor platform, we are not just offering another health platform - we are creating a new resource that provides accurate medical information, fosters a supportive community, and empowers patients worldwide," XO Life's team, stated on LinkedIn.
Details of the deal
- The fresh funding round was led by Oslo-based VC Sandwater and Grazia Equity, a Stuttgart-based venture capital firm that supports startups across Europe and co-invests in selected situations in the USA.
- The investment was also joined by Vi Partners, a Swiss venture capital firm specializing in tech and healthcare startups, and Bayern Kapital, a German venture capital firm that invests in tech startups with ticket sizes of up to €25 million. Additionally, existing investors such as escuvest, Isartal Ventures, Winning Mindset, MediVentures GmbH, and Capacura participated in the round.
- With the fresh capital raised, XO Life aims to further develop its platform and expand its reach internationally.
“This investment will enable us to advance our technology and expand internationally. Having proven our success in the German market, we are eager to address global health challenges and bring our innovative solutions to a wider audience," CEO of XO Life, Dr. Friderike Bruchmann, commented.
